Fig. 1From: Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinomaFlow diagram for the phase II study of radiotherapy with anti-PD-1 antibody as first-line therapy treating patients with unresectable iCCA. AE, adverse event; iCCA, intrahepatic cholangiocarcinoma; IO, immunotherapy; PD-1, programmed cell death-1; RT, radiotherapyBack to article page